Sirnaomics (2257) Fundamentals 2026 — Revenue Analysis | SniperIQ
Sirnaomics (2257) is a US-listed Healthcare company in Biotechnology with a market capitalization of HK$436M, trading at HK$4.00 on the HKSE. This SniperIQ fundamentals page covers Sirnaomics's valuation, profitability (net margin -17806.6%), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Sirnaomics's market cap?
Sirnaomics (2257) has a market capitalization of approximately HK$436M, trading at HK$4.00 on the HKSE. Market cap moves with the live share price.
How profitable is Sirnaomics?
Sirnaomics runs a net profit margin of -17806.6%, a gross margin of -999.6%, and an operating margin of -18871.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Sirnaomics pay a dividend?
Sirnaomics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Sirnaomics financially healthy?
Sirnaomics carries a debt-to-equity ratio of -0.94x and a current ratio of 0.40x, with a market beta of -0.03. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Sirnaomics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sirnaomics (2257) the key facts are: market cap HK$436M, 52-week range 3.76-22.78. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Sirnaomics's full fundamentals live
Get Sirnaomics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.